Defactinib


Meet the Mesothelioma Experts: Defactinib, a New Investigational Agent for Mesothelioma

On April 8 at 9 PM Eastern time, the Mesothelioma Applied Research Foundation (Meso Foundation) will hold a new installment of its ‘Meet the Experts’ series, featuring Dr. Joanna C. Horobin, the Chief Medical Officer at Verastem, Inc., who will discuss the company’s latest investigational agent, defactinib, which is being developed for use in patients with pleural […]


BREAKING NEWS: New Clinical Trial Opening

PRESS RELEASE
Contact Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com
CAMBRIDGE, MA – Sep. 10, 2013 – Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of COMMAND (Control Of Mesothelioma with MAiNtenance Defactinib). COMMAND is a registration-directed trial of lead cancer stem cell inhibitor […]